NICE — NSCLC

Dossier modules

• NICE_A

  Module A — Decision problem & technology

  required92%
• NICE_B

  Module B — Clinical effectiveness (SLR + RCTs)

  required67%
• NICE_C

  Module C — Cost effectiveness model (CEM, ICER, £/QALY)

  required66%
• NICE_D

  Module D — Budget impact analysis (BIA)

  required68%
• NICE_PAS

  Patient Access Scheme (PAS)

  90%
• NICE_EAG

  External Assessment Group report

  required46%

PICO questions (3)

1. NICE-PICO-01nice_scope
   P: Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy

   I: Test drug, monotherapy, q3w until progression

   C: pembrolizumab monotherapy; platinum doublet chemotherapy; atezolizumab

   O: overall survival, PFS, ORR, DoR, AEs ≥G3, HRQoL (EORTC QLQ-C30)
2. NICE-PICO-02nice_scope
   P: Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy

   I: Test drug, monotherapy, q3w until progression

   C: atezolizumab; platinum doublet chemotherapy

   O: overall survival, PFS, ORR, DoR, AEs ≥G3, HRQoL (EORTC QLQ-C30)
3. NICE-PICO-03nice_scope
   P: Adults with metastatic NSCLC, PD-L1 TPS≥50%, no prior systemic therapy

   I: Test drug, monotherapy, q3w until progression

   C: platinum doublet chemotherapy; atezolizumab; pembrolizumab monotherapy

   O: overall survival, PFS, ORR, DoR, AEs ≥G3, HRQoL (EORTC QLQ-C30)